• About
  • Policies
  • What is openaccess
  • Library
  • Contact
Advanced search
      View Item 
      •   BUIR Home
      • Scholarly Publications
      • Faculty of Science
      • Department of Molecular Biology and Genetics
      • View Item
      •   BUIR Home
      • Scholarly Publications
      • Faculty of Science
      • Department of Molecular Biology and Genetics
      • View Item
      JavaScript is disabled for your browser. Some features of this site may not work without it.

      p53 codon 72 polymorphism in bladder cancer-No evidence of association with increased risk or invasiveness

      Thumbnail
      View / Download
      81.4 Kb
      Author
      Törüner, G. A.
      Uçar, A.
      Tez, M.
      Çetinkaya, M.
      Özen, H.
      Özçelik, T.
      Date
      2001
      Source Title
      Urological Research
      Print ISSN
      0300-5623
      Publisher
      Springer
      Volume
      29
      Issue
      6
      Pages
      393 - 395
      Language
      English
      Type
      Article
      Item Usage Stats
      128
      views
      96
      downloads
      Abstract
      We studied the effect of the p53 gene Arg72Pro polymorphism on bladder cancer susceptibility in a case control study of 121 bladder cancer patients and 114 age-sex matched controls to determine whether this polymorphism is a biomarker for the risk and how aggressive the disease is. Genomic DNA was obtained from venous blood samples for genotype determination by PCR and restriction digestion. The genotype frequencies in the patient group were Arg/Arg: 0.3553, Arg/Pro: 0.4711, Pro/Pro: 0.1736, and in the control group Arg/Arg: 0.3684, Arg/Pro: 0.4825, Pro/Pro: 0.1491. The distribution of genotypes between the two groups was not statistically different (χ2 = 0.260, df: 2, P = 0.878). The patient group was subdivided into two groups as superficial bladder cancer (n = 88) and invasive bladder cancer (n = 33), according to the presence of muscle invasion. The distribution of genotypes in the superficial group was Arg/Arg: 0.3409, Arg/Pro: 0.5114, Pro/Pro: 0.1477 and in the invasive group Arg/Arg: 0.3940, Arg/Pro: 0.3636, Pro/Pro: 0.2424. No association was observed with the invasiveness of the tumor (χ2 = 2.542, df: 2, P = 0.281). Stratification of the data by tobacco exposure did not result in a significant difference in genotype frequencies. These data do not support an association between the p53 Arg72Pro polymorphism and bladder cancer.
      Keywords
      Bladder cancer
      Genetic susceptibility
      TP53 polymorphism
      Biological marker
      Protein p53
      Adult
      Aged
      Bladder carcinoma
      Cancer invasion
      Cancer risk
      Cancer susceptibility
      Cigarette smoking
      Controlled study
      Disease activity
      DNA polymorphism
      Female
      Gene frequency
      Genetic predisposition
      Genotype
      Histopathology
      Human
      Human tissue
      Major clinical study
      Male
      Polymerase chain reaction
      Priority journal
      Risk assessment
      Aged, 80 and over
      Female
      Genetic Predisposition to Disease
      Genotype
      Humans
      Middle Aged
      Neoplasm invasiveness
      Polymorphism, single nucleotide
      Risk factors
      Tumor Suppressor Protein p53
      Urinary Bladder Neoplasms
      Permalink
      http://hdl.handle.net/11693/24759
      Published Version (Please cite this version)
      http://dx.doi.org/10.1007/s002400100218
      Collections
      • Department of Molecular Biology and Genetics 426
      Show full item record

      Related items

      Showing items related by title, author, creator and subject.

      • Thumbnail

        TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT 

        Hill, R.; Madureira, P. A.; Ferreira, B.; Baptista, I.; Machado, S.; Colaço, L.; Dos Santos, M.; Liu, N.; Dopazo, A.; Ugurel, S.; Adrienn, A.; Kiss-Toth, E.; Isbilen, M.; Gure, A. O.; Link, W. (Nature Publishing Group, 2017)
        Intrinsic and acquired resistance to chemotherapy is the fundamental reason for treatment failure for many cancer patients. The identification of molecular mechanisms involved in drug resistance or sensitization is imperative. ...
      • Thumbnail

        The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelialmesenchymal transition in breast cancer 

        Raza, U.; Saatci, O.; Uhlmann, S.; Ansari, S. A.; Eyüpoglu, E.; Yurdusev, E.; Mutlu, M.; Ersan, P. G.; Altundağ, M. K.; Zhang, J. D.; Dogan, H. T.; Güler, G.; Şahin, Ö. (Impact Journals LLC, 2016)
        Tumor cells develop drug resistance which leads to recurrence and distant metastasis. MicroRNAs are key regulators of tumor pathogenesis; however, little is known whether they can sensitize cells and block metastasis ...
      • Thumbnail

        Adjuvant autologous melanoma vaccine for macroscopic stage III disease: survival, biomarkers, and improved response to CTLA-4 blockade 

        Lotem, M.; Merims, S.; Frank, S.; Hamburger, T.; Nissan, A.; Kadouri, L.; Cohen, J.; Straussman, R.; Eisenberg, G.; Frankenburg, S.; Carmon, E.; Alaiyan, B.; Shneibaum, S.; Ayyildiz, Z. O.; Isbilen, M.; Senses, K. M.; Ron, I.; Steinberg, H.; Smith, Y.; Shiloni, E.; Gure, A. O.; Peretz, T. (Hindawi Limited, 2016)
        Background. There is not yet an agreed adjuvant treatment for melanoma patients with American Joint Committee on Cancer stages III B and C. We report administration of an autologous melanoma vaccine to prevent disease ...

      Browse

      All of BUIRCommunities & CollectionsTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartmentsThis CollectionTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartments

      My Account

      Login

      Statistics

      View Usage StatisticsView Google Analytics Statistics

      Bilkent University

      If you have trouble accessing this page and need to request an alternate format, contact the site administrator. Phone: (312) 290 1771
      Copyright © Bilkent University - Library IT

      Contact Us | Send Feedback | Off-Campus Access | Admin | Privacy